Ishigaki Yasushi, Hirase Tetsuaki, Pathadka Swathi, Cai Zhihong, Sato Manaka, Takemura Ryo, Ishida Noriyuki
Division of Diabetes, Metabolism, and Endocrinology, Department of Internal Medicine, Iwate Medical University, Yahaba, Japan.
Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., Hyogo, Japan.
Diabetes Ther. 2024 Jan;15(1):245-256. doi: 10.1007/s13300-023-01484-4. Epub 2023 Oct 19.
Recent data on the prevalence of metabolic syndrome in Japanese patients with type 2 diabetes (T2D) are limited.
This retrospective, cross-sectional, observational study investigated the prevalence of metabolic syndrome in patients with T2D using a Japanese administrative claims database. Patients with a T2D diagnosis, prescription of a hypoglycemic agent, and one or more annual health checkups in 2020 were included. Trends in the prevalence of metabolic syndrome by sex and body mass index (BMI) subgroup were assessed.
The study cohort consisted of 155,653 patients (men, 81.6%; mean age 54.6 ± 8.5 years). Patients with metabolic syndrome had a higher mean BMI (29.1 ± 4.5 kg/m versus 25.2 ± 4.5 kg/m) and mean waist circumference (98.3 ± 10.0 cm versus 87.9 ± 11.2 cm) compared to those without metabolic syndrome. Overall, the prevalence of metabolic syndrome was 43.0% in patients with T2D, with prevalence higher in men (46.6%) than women (27.0%). The prevalence increased across BMI subgroups from 17.3% in the < 25 kg/m subgroup, to 54.6% and 66.1% in the 25 to < 30 and ≥ 30 kg/m subgroups, respectively. A greater proportion of patients with metabolic syndrome had cardiovascular or renal comorbidities (BMI < 25, 0.3-2.0%; BMI 25 to < 30, 0.7-6.2%; BMI ≥ 30 kg/m, 0.7-6.8%) and cardiovascular drug usage (BMI < 25, 1.3-9.0%; BMI 25 to < 30, 3.8-31.1%; BMI ≥ 30 kg/m, 3.5-37.0%) in the higher BMI subgroups compared to the BMI < 25 kg/m subgroup.
The prevalence of metabolic syndrome in Japanese patients with T2D was 43.0% and increased with higher BMI. In patients with T2D and metabolic syndrome, cardiovascular drug usage and comorbidities increased in patients with a higher BMI. These data highlight the importance of managing metabolic parameters in addition to glycemic control in Japanese patients with T2D, particularly in patients with metabolic syndrome and BMI ≥ 25 kg/m.
关于日本2型糖尿病（T2D）患者代谢综合征患病率的最新数据有限。
这项回顾性、横断面观察性研究使用日本行政索赔数据库调查了T2D患者代谢综合征的患病率。纳入2020年有T2D诊断、降糖药物处方且进行了一次或多次年度健康检查的患者。评估了按性别和体重指数（BMI）亚组划分的代谢综合征患病率趋势。
研究队列包括155,653名患者（男性占81.6%；平均年龄54.6±8.5岁）。与无代谢综合征的患者相比，代谢综合征患者的平均BMI更高（分别为29.1±4.5kg/m²和25.2±4.5kg/m²），平均腰围更大（分别为98.3±10.0cm和87.9±11.2cm）。总体而言，T2D患者中代谢综合征的患病率为43.0%，男性患病率（46.6%）高于女性（27.0%）。代谢综合征患病率在各BMI亚组中呈上升趋势，从BMI＜25kg/m²亚组的17.3%，分别升至25至＜30kg/m²亚组的54.6%和≥30kg/m²亚组的66.1%。与BMI＜25kg/m²亚组相比，BMI较高亚组中患有代谢综合征且有心血管或肾脏合并症的患者比例更高（BMI＜25，0.3 - 2.0%；BMI 25至＜30，0.7 - 6.2%；BMI≥30kg/m²，0.7 - 6.8%），且心血管药物使用比例更高（BMI＜25，1.3 - 9.0%；BMI 25至＜30，3.8 - 31.1%；BMI≥30kg/m²，3.5 - 37.0%）。
日本T2D患者中代谢综合征的患病率为43.0%，且随BMI升高而增加。在患有T2D和代谢综合征的患者中，BMI较高的患者心血管药物使用和合并症增多。这些数据凸显了在日本T2D患者中，除血糖控制外管理代谢参数的重要性，尤其是在患有代谢综合征且BMI≥25kg/m²的患者中。
